UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q /A

(Amendment No. 1)10-Q/A

 

(Mark One)

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2018March 31, 2019

 

[  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

COMMISSION FILE NUMBER: 333-208293

 

CANBIOLA, INC.Canbiola. inc.

(Exact name of Registrant as specified in its charter)

 

Florida

Florida

20-3624118

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

960 South Broadway, Suite 120

Hicksville NY 11801

 (Address(Address of principal executive offices)

 

(516) 590-1846595-9544

(Registrant’s telephone number, including area code)

 


 (Former(Former name, former address and former fiscal, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 




Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large“large accelerated filer,accelerated“accelerated filer,smaller“smaller reporting company, and emerging“emerging growth companycompany” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

[  ]

Accelerated filer

[  ]

Non-accelerated filer

[  ]

Smaller reporting company

[X]

Emerging Growth Company

[X]
(Do not check if smaller reporting company)

Emerging Growth Company


 



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ] Yes [X] No


The number of shares of the registrantsregistrant’s only class of common stock issued and outstanding as of May 17, 2019 was 552,992,664 shares.

September 13, 2018was 324,021,356 shares.EXPLANATORY NOTE




2



EXPLANATORY NOTE


The auditors of Canbiola, Inc. (the “Company”) found certain scrivener’s errors within the Consolidated Financial Statements, the accompanying Notes to Consolidated Financial Statements, and the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of the Company’sinadvertently provided an incorrect contact phone number in its Quarterly Report on Form 10-Q for the fiscal quarterperiod ended June 30, 2018March 31, 2019 (the “Original Filing”). and did not include interactive data (aka XBRL’s) for the Original Filing. This Amendment No. 1 on Form 10-Q/A (“Amendment No. 1”) amendsis being filed solely to include the Company’s interactive data and restatesto amend the Original Filing to correct the errors.Company’s phone number.






CANBIOLA, INC.

FORM 10-Q10-Q/A

June 30, 2018March 31, 2019

 

TABLE OF CONTENTS

 

Page No.

Page No.

PART I. - FINANCIAL INFORMATION

Item 1.

Financial Statements

3

Consolidated Balance Sheets June 30, 2018March 31, 2019 and December 31, 2017

2018

5

3

Consolidated Statements of Operations – Three and Six Months Ended June 30,March 31, 2019 and 2018 and 2017

6

4

Consolidated Statements of Cash Flows – SixThree Months Ended June 30,March 31, 2019 and 2018  and 2017

7

5

Condensed Notes to Unaudited Consolidated Financial Statements.

9

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

27

23

Item 3.

3

Quantitative and Qualitative Disclosures About Market Risk.

29

24

Item 4.

4

Controls and Procedures.

29

24

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

30

24

Item 1A.

Risk Factors

30

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

30

24

Item 3.

Defaults Upon Senior Securities

31

25

Item 4.

Mine Safety Disclosures

31

25

Item 5.

Other Information

31

25

Item 6.

Exhibits

32

25

 

2















4



PART 1I - FINANCIAL INFORMATION

 

Item 1.

Financial Statements.

Canbiola, Inc. and Subsidiary

Consolidated Balance Sheets

 

 

June 30,

 

December 31,

 

 

2018

 

 

2017

Assets

 

(Unaudited)

 

 

 

Current assets:

 

 

 

 

 

   Cash and cash equivalents

 

$

73,572 

 

 

$

1,652 

   Accounts receivable, less allowance for doubtful

      accounts of $0 and $0, respectively

 

14,132 

 

 

6,075 

   Inventory

 

7,122 

 

 

9,834 

   Note receivable - current

 

75,000 

 

 

75,000 

   Prepaid expenses - current

 

879,744 

 

 

64,911 

   Total current assets

 

1,049,570 

 

 

157,472 

 

 

 

 

 

 

Property and equipment, at cost less accumulated

 

 

 

 

 

   depreciation of $21,852 and $20,248, respectively

 

47,899 

 

 

11,148 

 

 

 

 

 

 

Other assets:

 

 

 

 

 

   Security Deposit

 

11,687 

 

 

11,687 

   Prepaid expenses - noncurrent

 

244,518 

 

 

 

   Note receivable - noncurrent

 

39,000 

 

 

39,000 

   Total other assets

 

295,205 

 

 

50,687 

 

 

 

 

 

 

Total assets

 

$

1,392,674 

 

 

$

219,307 

 

 

 

 

 

 

Liabilities and Stockholders' Deficiency

 

 

 

 

 

Current liabilities:

 

 

 

 

 

   Notes and loans payable

 

$

261,669 

 

 

$

193,504 

   Derivative Liability

 

727,086 

 

 

1,451,137 

   Accounts payable

 

132,368 

 

 

143,274 

   Accrued officers compensation

 

171,250 

 

 

98,750 

   Other accrued expenses payable

 

68,901 

 

 

62,539 

   Total current liabilities and total liabilities

 

1,361,274 

 

 

1,949,204 

Commitments and contingencies (Notes 12 and 13)

 

 

 

 

 

 

 

 

 

 

 

Stockholders' deficiency:

 

 

 

 

 

   Preferred stock, authorized 5,000,000 shares:

 

 

 

 

 

      Series A Preferred stock, no par value:

 

 

 

 

 

        authorized 20 shares, issued and outstanding

 

 

 

 

 

        13 and 8 shares, respectively

 

1,786,537 

 

 

243,537 

      Series B Preferred stock, $0.001 par value:

 

 

 

 

 

        authorized 500,000 shares, issued and outstanding

 

 

 

 

 

        365,089 and 157,985 shares, respectively

 

344 

 

 

150 

   Common stock, no par value; authorized

 

 

 

 

 

      750,000,000 shares, issued and outstanding

 

 

 

 

 

       244,017,230 and 225,572,323

 

 

 

 

 

      shares, respectively

 

13,028,907 

 

 

12,524,042 

   Additional Paid-in capital

 

346,406 

 

 

149,850 

   Additional Paid-in capital – Stock Options (Note 10)

 

84,000 

 

 

   Accumulated deficit

 

(15,214,794)

 

 

(14,647,476)

   Total stockholders' deficiency

 

31,400 

 

 

(1,729,897)

 

 

 

 

 

 

Total liabilities and stockholders' deficiency

 

$

1,392,674 

 

 

$

219,307 


Canbiola, Inc. and Subsidiary

Consolidated Balance Sheets

  March 31, 2019  December 31, 2018 
Assets        
Current assets:        
Cash and cash equivalents $567,291  $807,747 
Accounts receivable, less allowance for doubtful
accounts of $0 and $0, respectively
  324,449   39,172 
Inventory  77,110   87,104 
Prepaid expenses - current  238,079   210,351 
Deposit - current  150,000   - 
Total current assets  1,356,929   1,144,374 
         
Property and equipment, at cost less accumulated depreciation of $34,738 and $20,248, respectively  743,368   59,619 
         
Other assets:        
Deposit - noncurrent  19,787   48,726 
Prepaid expenses - noncurrent  2,061,356   2,365,719 
Note receivable - noncurrent  19,389   19,389 
Intangible assets, net of accumulated amortization of $2,194 and $0, respectively  196,461   - 
Goodwill (Note 4)  55,849   55,849 
Right-of-Use Asset  90,591   - 
Total other assets  2,443,433   2,489,683 
         
Total assets $4,543,730  $3,693,675 
         
Liabilities and Stockholders’ Deficiency        
Current liabilities:        
Notes and loans payable $17,370  $19,205 
Accounts payable  126,747   73,059 
Accrued officers compensation  68,750   68,750 
Other accrued expenses payable  44,955   43,778 
Current portion of lease liability  31,466   - 
Total current liabilities  289,288   204,792 
         
Non-current portion of lease liability  59,125   - 
         
Total liabilities  348,413   204,792 
         
Commitments and contingencies (Notes 14)        
         
Stockholders’ deficiency:        
Preferred stock, authorized 5,000,000 shares:        
Series A Preferred stock, no par value: authorized 20 shares, issued and outstanding 17 and 18 shares, respectively  4,546,924   4,557,424 
Series B Preferred stock, $0.001 par value: authorized 500,000 shares, issued and outstanding 342,853 and 499,958 shares, respectively  322   479 
Common stock, no par value; authorized 750,000,000 shares, issued and outstanding 548,487,714 and 440,566,325 shares, respectively  18,531,529   16,624,557 
Additional Paid-in capital  872,976   872,976 
Additional Paid-in capital – Stock Options (Note 12)  202,200   202,200 
Accumulated deficit  (19,958,634)  (18,768,753)
Total stockholders’ deficiency  4,195,317   3,488,883 
         
Total liabilities and stockholders’ deficiency $4,543,730  $3,693,675 

See notes to consolidated financial statements.




3

Canbiola, Inc. and Subsidiary

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

Six Months Ended June 30,

 

Three Months Ended June 30,

 

 

2018

 

 

2017

 

 

2018

 

 

2017

Revenues

 

 

 

 

 

 

 

 

 

 

 

   Service Revenue

 

$

12,757 

 

 

$

41,707 

 

 

$

5,957 

 

 

$

23,735 

   Product Sales

 

211,203 

 

 

2,135 

 

 

148,234 

 

 

2,135 

Total Revenues

 

223,960 

 

 

43,842 

 

 

154,191 

 

 

25,870 

   Cost of product sales

 

91,439 

 

 

1,139 

 

 

46,852 

 

 

1,139 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

132,521 

 

 

42,703 

 

 

107,339 

 

 

24,731 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

   Officers compensation

 

136,250 

 

 

38,832 

 

 

76,250 

 

 

19,377 

   Consulting fees (including stock-based compensation of $572,777

 

 

 

 

 

 

 

 

 

 

 

       $37,229, $344,869 and $26,229, respectively)

 

643,676 

 

 

71,782 

 

 

367,769 

 

 

55,082 

    Directors fees (including stock-based compensation of $185,400,

 

 

 

 

 

 

 

 

 

 

 

       $0, $0 and $0, respectively)

 

185,400 

 

 

 

 

(17,400)

 

 

   Advertising expense

 

37,008 

 

 

21,510 

 

 

14,675 

 

 

20,893 

   Hosting expense

 

7,478 

 

 

14,687 

 

 

3,810 

 

 

12,246 

   Rent expense

 

33,065 

 

 

32,530 

 

 

16,800 

 

 

16,265 

   Professional fees

 

70,339 

 

 

62,736 

 

 

56,956 

 

 

46,758 

   Depreciation of property and equipment

 

1,604 

 

 

1,614 

 

 

801 

 

 

807 

   Amortization of intangible assets

 

 

 

1,986 

 

 

 

 

993 

   Other

 

120,827 

 

 

60,519 

 

 

56,113 

 

 

38,775 

 

 

 

 

 

 

 

 

 

 

 

 

   Total operating expenses

 

1,235,647 

 

 

306,196 

 

 

575,774 

 

 

211,196 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

(1,103,126)

 

 

(263,493)

 

 

(468,435)

 

 

(186,465)

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

   Interest income

 

5,024 

 

 

586 

 

 

2,512 

 

 

293 

   Income (expense) from derivative liability

 

844,051 

 

 

(53,655)

 

 

(231,655)

 

 

(250,334)

   Loss on stock issuance

 

(185,104)

 

 

 

 

(185,104)

 

 

   Loss on debt conversion

 

(57,738)

 

 

 

 

(57,738)

 

 

   Interest expense (including amortization of debt discounts of $54,165,

      $153,105, $25,701 and $65,375, respectively)

 

(70,425)

 

 

(167,786)

 

 

(34,456)

 

 

(71,942)

 

 

 

 

 

 

 

 

 

 

 

 

   Other income (expense) – net

 

535,808 

 

 

(220,855)

 

 

(506,441)

 

 

(321,983)

 

 

 

 

 

 

 

 

 

 

 

 

Loss before provision for income taxes

 

(567,318)

 

 

(484,348)

 

 

(974,876)

 

 

(508,448)

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss and comprehensive loss

 

$

(567,318)

 

 

(484,348)

 

 

(974,876)

 

 

(508,448)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share – basic and diluted

 

 

 

 

 

 

 

 

 

 

 

   Basic

 

$

(0.00)

 

 

$

(0.00)

 

 

$

(0.00)

 

 

$

(0.00)

   Diluted

 

$

(0.00)

 

 

$

(0.00)

 

 

$

(0.00)

 

 

$

(0.00)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding –

 

 

 

 

 

 

 

 

 

 

 

   Basic

 

232,957,482 

 

 

153,334,334 

 

 

236,270,276 

 

 

158,836,059 

   Diluted

 

371,751,524 

 

 

267,980,990 

 

 

377,833,277 

 

 

278,278,009 

 

 

 

 

 

 

 

 

 

 

 

 

See notes to consolidated financial statements.




Canbiola, Inc. and Subsidiary

Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Six Months Ended June 30,

 

 

 

2018

 

 

2017

Operating Activities:

 

 

 

 

 

 

 Net loss

 

 

$

(567,318)

 

 

$

(484,348)

   Adjustments to reconcile net loss to net

 

 

 

 

 

 

      cash used in operating activities:

 

 

 

 

 

 

      Stock-based compensation, net of prepaid stock-     

         based consulting fees

 

 

758,177 

 

 

37,229 

      Loss on stock issuance   

 

 

185,104 

 

 

      Loss on debt conversion   

 

 

57,738 

 

 

      Debt issuance expense   

 

 

14,000 

 

 

      Expense from derivative liability   

 

 

(844,051)

 

 

53,655 

      Depreciation of property and equipment   

 

 

1,604 

 

 

1,614 

      Amortization of intangible assets

 

 

 

 

1,986 

      Amortization of debt discounts

 

 

54,165 

 

 

153,105 

   Changes in operating assets and liabilities:

 

 

 

 

 

 

      Accounts receivable

 

 

(8,057)

 

 

(10,948)

      Inventory

 

 

2,712 

 

 

(10,946)

      Prepaid expenses

 

 

 

 

2,500 

      Accounts payable

 

 

(10,906)

 

 

48,896 

      Accrued officers compensation

 

 

72,500 

 

 

36,000 

      Other accrued expenses payable

 

 

10,607 

 

 

17,321 

 

 

 

 

 

 

 

   Net cash used in operating activities

 

 

(273,725)

 

 

(153,936)

 

 

 

 

 

 

 

Investing Activities:

 

 

 

 

 

 

   Fixed assets additions

 

 

(38,355)

 

 

 

 

 

 

 

 

 

   Net cash used in investing activities

 

 

(38,355)

 

 

 

 

 

 

 

 

 

Financing Activities:

 

 

 

 

 

 

   Proceeds received from notes and loans payable

 

 

135,000 

 

 

124,000 

   Proceeds from sale of Series B preferred stock

 

 

249,000 

 

 

 

 

 

 

 

 

 

   Net cash provided by financing activities

 

 

384,000 

 

 

124,000 

 

 

 

 

 

 

 

Increase (decrease) in cash and cash equivalents

 

 

71,920 

 

 

(29,936)

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

 

1,652 

 

 

30,193 

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

 

$

73,572 

 

 

$

257 

 

 

 

 

 

 

 




SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

    Income taxes paid

 

 

$

 

 

$

Interest paid

 

 

$

 

 

$

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

    Issuance of common stock in satisfaction of debt

 

 

$

15,000 

 

 

$

65,000 

 

 

 

 

 

 

 

    Issuance of common stock in satisfaction of directors fees

 

 

$

185,400 

 

 

$

 

 

 

 

 

 

 

    Issuance of common stock in satisfaction of accrued interest

 

 

$

4,246 

 

 

$

7,837 


Canbiola, Inc. and Subsidiary


Consolidated Statements of Operations and Comprehensive Loss

Three Months Ended March 31, 2019 and 2018

(Unaudited)

  2019  2018 
Revenues        
Product Sales $515,360  $62,969 
Service Revenue  1,800   6,800 
Total Revenues  517,160   69,769 
Cost of product sales  262,553   44,587 
Gross Profit  254,607   25,182 
         
Operating costs and expenses:        
Officers and directors compensation (including stock- based compensation of $262,420 and $202,800 respectively)  445,550   262,800 
Consulting fees (including stock-based compensation of $565,776 and $11,000, respectively)  663,751   275,908 
Advertising expense  26,388   22,333 
Hosting expense  450   3,668 
Rent expense  11,860   16,265 
Professional fees  37,836   13,383 
Depreciation of property and equipment  2,765   803 
Amortization of intangible assets  2,194   - 
Other  235,881   64,713 
         
Total operating expenses  1,426,675   659,873 
         
Loss from operations  (1,172,068)  (634,691)
         
Other income (expense):        
Interest income  -   2,512 
Income (expense) from derivative liability  -   1,075,706 
Interest expense (including amortization of debt discounts of $0 and $28,464, respectively)  (446)  (35,969)
         
Other income (expense) - net  (446)  1,042,249 
         
Income (Loss) before provision for income taxes  (1,172,514)  407,558 
         
Provision for income taxes  -   - 
         
Net income (loss) and comprehensive loss $(1,172,514) $407,558 
         
Net income (loss) per common share - basic and diluted $(0.00) $0.00 
         
Weighted average common shares outstanding –        
Basic  501,585,684   229,607,879 
Diluted  732,708,830   365,602,196 

See notes to consolidated financial statements.




4

Canbiola, Inc. and Subsidiary

Consolidated Statements of Cash Flows

(Unaudited)

  Three Months Ended March 31, 
  2019  2018 
Operating Activities:        
Net income $(1,172,514) $407,558 
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation, net of prepaid stock-
based consulting fees
  828,196   430,708 
Expense from derivative liability  -   (1,075,707)
Depreciation of property and equipment - General  2765   803 
Depreciation of property and equipment - COGS  5,198   - 
Amortization of intangible assets  2,194   - 
Amortization of debt discounts  -   28,464 
Changes in operating assets and liabilities:        
Accounts receivable  (285,277)  (5,720)
Inventory  9,994   1,172 
Security deposit  (121,061)  - 
Accounts payable  38,819   (52,274)
Accrued officers compensation  -   52,500 
Other accrued expenses payable  1,177   4,291 
         
Net cash used in operating activities  (690,509)  (208,205)
         
Investing Activities:        
Intangible assets additions  (50,000)  - 
Fixed assets additions  (694,212)  (13,330)
         
Net cash used in investing activities  (744,212)  (13,330)
         
Financing Activities:        
Repayments of notes and loans payable  (1,835)  - 
Proceeds received from notes and loans payable  -   25,000 
Proceeds from sale of common stock  1,196,100   - 
Proceeds from sale of Series B preferred stock  -   249,000 
         
Net cash provided by financing activities  1,194,265   274,000 
         
Increase (decrease) in cash and cash equivalents  (240,456)  52,465 
         
Cash and cash equivalents, beginning of period  807,747   1,652 
         
Cash and cash equivalents, end of period $567,291  $54,117 
         
SUPPLEMENTAL CASH FLOW INFORMATION:        
Income taxes paid $-  $- 
Interest paid $-  $- 
         
NON-CASH INVESTING AND FINANCING
ACTIVITIES:
        
        
Issuance of common stock in acquisition of Intangible assets $148,655  $- 
Issuance of common stock in satisfaction of Officers compensation $54,340  $- 
Issuance of common stock in satisfaction of directors fees $-  $202,800 
Issuance of common stock for services rendered $497,220  $- 

See notes to consolidated financial statements.

5

Canbiola, Inc. and Subsidiary

Notes to Consolidated Financial Statements

SixThree Months Ended June 30,March 31, 2019 and 2018 and 2017

(Unaudited)


NOTE 1 – Organization and Description of Business


Canbiola, Inc. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), a New York corporation incorporated on April 2, 2008. On May 15, 2017, WRAP changed its name to Canbiola, Inc. (the “Company” or “CANB” or “Canbiola”). The Company operates several divisions, including document management and email marketing platforms and a division specializing in the sale of products containing CBD. The Company used to operate its document and information platform from its wholly owned subsidiary, Prosperity Systems, Inc; however, after the acquisition of Prosperity, the Company transferred Prosperity’s operations to WRAP and is presently in the process of dissolving Prosperity. ForThe Company acquired 100% of the periods presented,membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company formed Duramed, Inc., a Nevada corporation (“Duramed”) in November 2018, to facilitate the assets, liabilities, revenues,manufacture and expenses are thosesale of CANB. Prosperity had no activity for the periods presented.durable medical equipment incorporating CBD.


Effective December 27, 2010, WRAP effected a 10 for 1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1 for 10 reverse stock split of its common stock. The accompanying consolidated financial statements retroactively reflect these stock splits.


On May 15, 2017, WRAP changed its name to Canbiola, Inc. (the “Company” or “CANB” or “Canbiola”).

Canbiola Inc. is a US Company specializingspecializes in the production and sale of a variety of hemp derived Cannabidiol (CBD) based(“CBD”) products derived from Hemp, such as oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola is developing theirits own line of proprietary products as well as seeking synergistic value through acquisitions in the Hemp Industry. Canbiola aims to be the premier provider of the highest quality Hemp derived naturalhemp CBD products on the market through sourcing the very best raw material and developing a variety of products we believe will improve people'speople’s lives in a variety of areas.


CANB expectsThe Company also operates document management and email marketing platforms. The Company used to concentrateoperate its future business activities ondocument and information platform from its wholly owned subsidiary, Prosperity Systems, Inc; however, after the saleacquisition of CBD productsProsperity, the Company transferred Prosperity’s operations to the Company directly.

For the periods presented, the assets, liabilities, revenues, and does not plan to market or further develop its technology products.expenses are those of CANB. Prosperity had no activity for the periods presented. Financial information for PHP and Duramed in the periods have been consolidated with the Company’s financials.


NOTE 2 – Going Concern Uncertainty


The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of June 30, 2018,March 31, 2019, the Company had cash and cash equivalents of $73,572$567,291 and a working capital deficit of $534,406.$1,067,641. For the sixthree months ended June 30,March 31, 2019 and 2018, and 2017, the Company had net loss of $567,318$1,172,514 and $484,348,a gain of $407,558, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company plans to improve its financial condition by raising capital through sales of shares of its common stock. Also, the Company plans to expand its operation of CBD products to increase its profitability. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.


NOTE 3 – Summary of Significant Accounting Policies


(a) Principles of Consolidation

 

The consolidated financial statements include the accounts of CANB and its wholly owned subsidiary Prosperity from the date of its acquisition on January 5, 2015.subsidiaries, Pure Health products, Duramed, and Prosperity. All intercompany balances and transactions have been eliminated in consolidation.




6

The Company considers Pure Health products to be a variable interest entity as prescribed under Accounting guidelines. Due to the fact that the company is not dependent on Pure Health Products solely for manufacture, no consolidation of Pure Heath Products financial information is required.


(b) Use of Estimates


The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.


(c) Fair Value of Financial Instruments


The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value.


Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:


Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.


Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.


Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.


(d) Cash and Cash Equivalents


The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents.


(e) Inventory


All inventories are finished goods and stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method.


(f) Property and Equipment, Net


Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred.




(g) Intangible Assets, Net


Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets.


7

(h) Goodwill and Intangible Assets with Indefinite Lives


The Company does not amortize goodwill and intangible assets with indefinite useful lives, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded.


(i) Long-lived Assets


The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.

 

(j) Revenue Recognition


The Company recognizes service revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over agreed periodstime or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Private Label Customers, Global CBD, LLC and TZ Wholesale, are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to customersCompany specifications, and recognizesshipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped.

Revenue from product sales upon shipment ofis recognized when an order has been obtained, the ordered products to customers, provided there are no uncertainties regarding customer acceptance, persuasive evidence of an arrangement exists; the sales price is fixed or determinable;and determinable, the product is shipped, title has transferred, and collectability is deemed probable.reasonably assured.

The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis.

 

(k) Cost of Product Sales

The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products.

8

(l) Stock-Based Compensation


Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments to Non-Employees.”


In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions.


In accordance with ASC 505-50, the Company determines the fair value of the stock based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete.


Options and warrants


The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:




Risk-Free Interest Rate.


We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.


Expected Volatility.


We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock.

 

Dividend Yield.


We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.

 

Expected Term.


The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant.


Forfeitures.


Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.


9

(l)

(m) Advertising


Advertising costs are expensed as incurred and amounted to $37,008$26,388 and $21,510$22,333 for the six monthsperiod ended June 30,March 31, 2019 and 2018, and 2017, respectively.


(m)(n) Research and Development


Research and development costs are expensed as incurred. In the period ended March 31, 2019 and 2018, the Company spent $17,500 and $2,500 in research and development which was expenses as spent, respectively.


(n)(o) Income Taxes


Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized.




The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability.


(o)(p) Net Income (Loss) per Common Share


Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period.


Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 7, 8 and 10).


(p)(q) Recent Accounting Pronouncements


In May 2014, the FASB issued ASU 2014-09 "Revenue“Revenue from Contracts with Customers"Customers” (Topic 606) which establishes revenue recognition standards. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The impact of ASU 2014-09 on the Company’s financial statements has not been significant.


In 2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. ASU 2016-2 isEffective January 1, 2019, we adopted this new accounting guidance using the effective for fiscal years beginning after December 15, 2018. The impact ondate transition method, which permits entities to apply the Company's financial statements is not expectednew lease standards using a modified retrospective transition approach at the date of adoption. As such, historical periods will continue to be significant.measured and presented under the previous guidance while current and future periods subject to this new accounting guidance. Upon adoption we recorded a $100,681 right-of-use asset related to our one operating lease (see Note 13) and a $90,591 lease liability.


(q)(r) Reclassifications


Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company'sCompany’s previously reported net income.


10

NOTE 4 – Acquisition of Pure Health Products, LLC

Effective December 28, 2018, CANB acquired 100% ownership of Pure Health Products, LLC (“Pure Health”) in exchange for the cancellation of CANB’s $75,000 note receivable from Pure Health and $10,827 accrued interest thereon and issuance of 3,096,827 newly issued shares of CANB common stock (valued at the $0.0578 closing trading price on December 28, 2018 or $178,997, see Note 11). The acquisition has been accounted for in the accompanying consolidated financial statements as a purchase transaction. Accordingly, the financial position and results of operations of Pure Health prior to the date of the acquisition have been excluded from the accompanying consolidated financial statements.

The estimated fair values of the identifiable net assets of Pure Health at December 28, 2018 (effective date of acquisition) consisted of:

Cash and cash equivalents $404 
Accounts receivable from CANB  16,676 
Inventory  79,652 
Property and equipment, net  7,559 
     
Security deposit  2,100 
     
Total assets  106,391 
     
Accounts payable, including $34,419 due to CANB  49,825 
     
Total liabilities  49,825 
     
Identifiable net assets $56,566 

Goodwill of $55,849 (excess of the $112,415 fair value of the 3,096,827 shares of CANB common stock issued to Pure Health’s stockholders over the $56,566 identifiable net assets of Pure Health at December 28, 2018 after reflecting the $85,827 cancellation of the $75,000 note payable and $10,827 accrued interest) was recorded from the acquisition.

The following pro forma information summarizes the results of operations for the periods indicated as if the acquisition occurred at December 31, 2017. The pro forma information is not necessarily indicative of the results that would have been reported had the transaction actually occurred on December 31, 2017, nor is it intended to project results of operations for any future period.

  Three Months Ended 
  March 31, 
  2019  2018 
       
Product sales $515,360  $67,207 
         
Cost of product sales  262,553   42,607 
         
Gross profit on product sales  252,807   24,600 
         
Service revenue  1,800   6,800 
         
Total gross profit  254,607   31,400 
         
Operating expenses  1,426,675   673,665 
         
Loss from operations  (1,172,068)  (642,265)
         
Other income (loss) - net  (446)  1,042,249 
         
Net income (loss) $(1,172,514) $399,984 
Net income (loss) per common share- basic and diluted $(0.00) $0.00 
         
Weighted average common shares outstanding –        
Basic  501,585,684   229,607,879 
Diluted  732,708,830   365,602,196 

11

NOTE 5 – Inventories

Inventories consist of:

 March 31, 2019  December 31, 2018 
Raw materials $72,148  $79,652 
         
Finished goods  4,962   7,452 
Total $77,110  $87,104 


NOTE 46 – Notes Receivable


Notes receivable consist of:

 

 

 

 

 

June 30,

 2018

 

December 31,

 2017

Secured Promissory note dated October 17, 2017 due from Pure Health

        Products, LLC (“PHP”), interest at 12% per annum, due October

        17, 2018, secured by assets of PHP

 

$

75,000 

 

$

75,000 

 

 

 

 

 

Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020      

 

39,000 

 

39,000 

 

 

 

 

 

Total

 

114,000 

 

114,000 

 

 

 

 

 

Current portion of notes receivable

 

(75,000)

 

(75,000)

Noncurrent portion of notes receivable

 

$

39,000 

 

$

39,000 





Pursuant to an option Agreement dated November 10, 2017, the Company has an option expiring November 10, 2027 to purchase certain specified assets of Pure Health for $75,000, payable via cancellation of Pure Health’s obligations under the Secured Promissory Note or in cash or cash equivalent.Notes receivable consist of:


 March 31, 2019  December 31, 2018 
Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 $19,389  $19,389 
         
Total  19,389   19,389 
         
Current portion of notes receivable  -   - 
Noncurrent portion of notes receivable $19,389  $19,389 

Stock Market Manager, Inc is affiliated with Carl Dilley, a Company director. In 2018, the Company received services from Stock Market Manager valued at $19,611 in exchange for the cancellation of $19,611 in note receivables.

12


NOTE 57 – Property and Equipment, Net


Property and Equipment, net, consist of:


 

June 30,

 

December 31,

 

2018

 

2017

 March 31, 2019  December 31, 2018 

 

 

 

 

     

Furniture & Fixtures

 

$

19,018 

 

$

19,018 

 $19,018  $19,018 

 

 

 

 

        

Office Equipment

 

12,378 

 

12,378 

  12,378   20,992 

 

 

 

 

        

Manufacturing Equipment

 

38,355 

 

  746,710   46,384 

 

 

 

 

        

Total

 

69,751 

 

31,396 

  778,106   86,394 

 

 

 

 

        

Accumulated amortization

 

(21,852)

 

(20,248)

  (34,738)  (26,775)

 

 

 

 

        

Net

 

$

47,899 

 

$

11,148 

 $743,368  $59,619 


NOTE 68 – Intangible Assets, Net


Intangible assets, net, consist of:

 

 

June 30,

 

December 31,

 

 

2018

 

2017

 

 

 

 

 

Video conferencing software acquired

 

 

 

 

  by Prosperity in December 2009

 

$

30,000 

 

$

30,000 

 

 

 

 

 

Enterprise and audit software acquired

 

 

 

 

  by Prosperity in April 2008

 

20,000 

 

20,000 

 

 

 

 

 

Patent costs incurred by WRAP

 

6,880 

 

6,880 

 

 

 

 

 

Other

 

3,548 

 

3,548 

 

 

 

 

 

Total

 

60,428 

 

60,428 

 

 

 

 

 

Accumulated amortization and Impairment

 

(60,428)

 

(60,428)

 

 

 

 

 

Net

 

$

 

$


  March 31, 2019  December 31, 2018 
       
Video conferencing software acquired by Prosperity in December 2009 $30,000  $30,000 
         
Enterprise and audit software acquired by Prosperity in April 2008  20,000   20,000 
         
Patent costs incurred by WRAP  6,880   6,880 
         
CBD Technology  198,655   - 
         
Other  3,548   3,548 
         
Total  259,083   60,428 
         
Accumulated amortization and Impairment  (60,428)  (60,428)
         
Net $198,655  $0 

The aboveCBD related technology were purchased from Hudilab, Inc. (“HUDI”) and Seven Chakras, LLC (“Seven Chakras”) in the three months ended March 31, 2019. On January 14, 2019, the Company and PHP (collectively, the “buyer”) entered into a License and Acquisition Agreement (the “LAA”) with HUDI. Pursuant to the LAA, HUDI will sell the technology owned by it to the buyer in exchange for 7,500,000 shares of CANB common stock. On January 14, 2019, the shares were issued to the owner of HUDI and valued at $131,625. On January 31, 2019, PHP entered into an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC (“Seven Chakras”). Pursuant to the Agreement, PHP purchased the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ products containing cannabidiol (“CBD”), (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials (collectively, the “Assets”). On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock valued at $17,030 to owners of Seven Chakras as additional consideration, along with the $50,000 cash payments, pursuant to the agreement.

13

The other intangible assets relate to thedocument management and email marketing divisions. AtSince December 31, 2017, wethe Company do not expect any future positive cash flow from these divisions. Accordingly, we have recorded an impairment expense of $21,509 at December 31, 2017 and reduced the net carrying value of these intangible assets was reduced to $0.




NOTE 79 – Notes and Loans Payable


Notes and loans payable consist of:

 

 

 

 

 

June 30,

 2018

 

December 31,

 2017

 

 

 

 

 

Convertible notes payable to lender dated from March 15, 2016 (as amended June 2, 2016) to November 15, 2017, interest at rates ranging from 12% to 14.99% per annum, due from April 6, 2017 to May 15, 2018, partially converted at March 22, 2017 and the remaining notes convertible into Common Stock at a Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of the lowest Closing Bid Price of the Common Stock for the 30 Trading Days preceding the Conversion Date – net of

        unamortized debt discount of $0 and $1,815, respectively   

 

38,500

 

36,685

 

 

 

 

 

Convertible notes payable to lender dated February 1, 2016 (as amended

        December 21, 2016) and December 21, 2016, interest at 12% per

        annum, due February 1, 2017 and May 20, 2017, convertible into

        Common Stock at a Conversion Price equal to the lesser of (i) $0.01 per

        share or (ii) 50% of the lowest Closing Bid Price of the Common Stock

        for the 30 Trading Days preceding the Conversion Date – net of

        unamortized debt discount of $0 and $0, respectively. The note date dated  

        February 1, 2016 was fully converted at June 11, 2018     

 

50,000

 

65,000

 

 

 

 

 

Convertible notes payable to Pasquale and Rosemary Ferro dated from

        May 2, 2017 to May 4, 2018, interest at 12% per annum, due from

        September 16, 2017 to May 7, 2019 (as amended May 4, 2018),

        convertible into Common Stock at a Conversion Price equal to the lesser

        of (i) $0.01 per share or (ii) 50% of the lowest Closing Bid Price of the

        Common Stock for the 30 Trading Days preceding the Conversion Date –

        net of unamortized debt discount of $8,451 and $19,613, respectively     

 

105,049

 

73,887

 

 

 

 

 

Convertible note payable to lender dated August 8, 2017 interest at 12% per

        annum, due August 8, 2018, convertible into Common Stock at a

        Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of

        the lowest Closing Bid Price of the Common Stock for the 30 Trading

        Days preceding the Conversion Date – net of unamortized debt discount

        of $2,671 and $15,068, respectively     

 

22,329

 

9,932

 

 

 

 

 

Convertible note payable to lender dated June 6, 2018, interest at 12% per

        annum, due March 6, 2019, convertible into Common Stock at a

        Conversion Price equal to the lesser of 55% of the lowest Closing Bid  

.       Price of the Common Stock for the 25 Trading Days preceding the

       (i) Inception date or (ii) the Conversion Date – net of unamortized debt

        discount of $91,209 and $0, respectively     

 

22,791

 

-

 

 

 

 

 

Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due)

 

5,000

 

5,000

 

 

 

 

 

Note payable to Carl Dilley, a director of the Company, interest at 12.99% per annum, due February 1, 2021

 

15,000

 

-

 

 

 

 

 

Loan payable to Mckenzie Webster Limited (“MWL”), an entity controlled by the former Chairman of the Board of Directors of the Company, non-interest bearing, due on demand

 

3,000

 

3,000

Total

 

$

261,669

 

$

193,504





The derivative liability of the convertible notesNotes and loans payable consistsconsist of:


 

 

June 30, 2018

 

December 31, 2017

 

 

Face Value

 

Derivative Liability

 


Face Value

 

Derivative Liability

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible notes payable to lender dated from March 15, 2016 (as amended June 2, 2016) to November 15, 2017, due from April 6, 2017 to May 15, 2018

 







38,500

 




$




74,119

 







38,500

 

 




 248,597

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible notes payable to lender dated    

        February 1, 2016 (as amended

        December 21, 2016) and December 21,

        2016, due February 1, 2017 and May

        20, 2017.The note date dated  

        February 1, 2016 was fully converted at

        June 11, 2018     

 

 






50,000

 

 






96,258

 

 






65,000

 

 






418,889

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible notes payable to Pasquale and

        Rosemary Ferro dated from May 2,

        2017 to January 8, 2018, due from

        September 16, 2017 to May 7, 2019 (as

         amended May 4, 2018)   

 

 





113,500

 

 





258,669

 

 





93,500

 

 





611,886

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible notes payable to lender dated

        June 6, 2018, due March 6, 2019

 

 


114,000

 

 


248,184

 

 


-

 

 


-


Convertible notes payable to lender dated

        August 8, 2017, due August 8, 2018

 

 


25,000

 

 


49,856

 

 


25,000

 

 


171,765

 

 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

$

341,000

 

$

727,086

 

$

222,000

 

$

1,451,137

 March 31, 2019  December 31, 2018 
Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due)  5,000   5,000 
         
Note payable to Carl Dilley, a director of the Company, interest at 12.99% per annum, due February 1, 2021  10,899   10,899 
         
Loan payable to Mckenzie Webster Limited (“MWL”), an entity controlled by the former Chairman of the Board of Directors of the Company, non-interest bearing, due on demand  3,000   3,000 
         
Total $18,899  $18,899 


The above convertible notes contain a variable conversion feature based on the future trading price of the Company common stock. Therefore, the number of shares of common stock issuable upon conversion of the notes is indeterminate. Accordingly, we have recorded the fair value of the embedded conversion features as a derivative liability at the respective issuance dates (or amendment dates) of the notes ($460,316 total for the six months ended June 30, 2018) and charged the applicable amounts to debt discounts ($120,000 total for the six months ended June 30, 2018) and the remainder to other expense ($340,316 total for the six months ended June 30, 2018). The increase (decrease) in the fair value of the derivative liability from the respective issuance dates (or amendment dates) of the notes to the measurement date ($1,160,391 total decrease for the six months ended June 30, 2018) is charged (credited) to other expense (income). The fair value of the derivative liability of the notes is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculations of the derivative liability of the notes at June 30, 2018 include (1) stock price of $0.0215 per share, (2) exercise price of $0.0074 per share, (3) terms ranging from 0 days to 311 days, (4) expected volatility of 269% and (5) risk free interest rates ranging from 0.00% to 2.24%.




NOTE 89 – Preferred Stock


Each share of Series A Preferred Stock is convertible into 10,000,000 shares of CANB common stock and is entitled to 20,000,000 votes.


Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shareshares of Series B Preferred Stock hashave no voting rights.


The Company issued a total of 10 shares of CANB Series A Preferred Stock (5 shares to Mckenzie Webster Limited  and 5 shares to Marco Alfonsi) in exchange for the retirement of a total of 100,000,000 shares of CANB common stock (50,000,000 shares from Mckenzie Webster Limited and 50,000,000 shares from Marco Alfonsi).


On October 4, 2017, the Company issued 3 shares of CANB Series A Preferred Stock to Alfonsi: 2 shares were the consideration for Alfonsi’s cancellation of accrued salaries payable of $127,803 owed to Alfonsi and 1 share (valued at $63,902) was issued pursuant to the new employment agreement with Alfonsi.


On November 30, 2017, MWL converted its 5 shares of CANB Series A Preferred Stock to 50,000,000 shares of CANB common stock.


On December 5, 2017, the Company issued 157,985 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to a Securities Purchase Agreement (the “SPA”) dated October 13, 2017, in exchange for proceeds of $150,000, or $0.95 per CANB Series B Preferred share.


On January 22, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share.


On February 12, 2018, the Company issued 1 share of CANB Series A Preferred Stock to David Posel pursuant to a service agreement. The fair value of the issuance is $373,000 and will be amortized over the vesting period of four years.


On February 16, 2018, the Company issued 3 shares of CANB Series A Preferred Stock to David PoselAndrew Holtmeyer pursuant to a service agreement. The fair value of the issuance is $1,020,000 and will be amortized over the vesting period of one year.


On February 16, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share.


On March 20, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share.




On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, RedDiamond Partners converted its 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock to 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock, respectively.


14

On May 14, 2018, the Company issued 1 share of CANB Series A Preferred Stock to a consultant pursuant to a Consulting Agreement dated May 11, 2018. The $150,000 fair value of the issuance was partially charged to consulting fees in the three months ended JuneSeptember 30, 2018.


NOTE 9 – CommonFrom July 24, 2018 to September 26, 2018, RedDiamond Partners converted aggregately 263,263 shares of CANB Series B Preferred Stock to 53,839,743 shares of CANB common stock.


On FebruaryAugust 28, 2018, September 14, 2018 and September 19, 2018, the Company issued 36,842 shares, 105,263 shares, and 105,263 shares of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $35,000, $100,000 and $100,000, respectively, or $0.95 per CANB Series B Preferred share.

From October 2, 2017,2018 to November 7, 2018, RedDiamond Partners converted aggregately 101,736 shares of CANB Series B Preferred Stock to 13,094,733 shares of CANB common stock.

On October 23, 2018 and November 14, 2018, the Company issued 200,000 shares and 52,500 shares of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) in exchange for proceeds of $190,000 and $49,875, respectively, or $0.95 per CANB Series B Preferred share.

On December 28,2018, Marco Alfonsi converted 3 shares of CANB Series A Preferred Stock to 30,000,000 shares of CANB common stockstock.

On December 29, the Company issued 8 shares of CANB Series A Preferred Stock to a financial consultant for services rendered.three officers of the company (1 share to Stanley L. Teeple, 5 shares to Pasquale Ferro and 2 shares to Andrew Holtmeyer), pursuant to the employment agreements with them. The $11,000 fair value of the 200,000 sharesissuance totaled at $4,624,000 and will be amortized over the vesting period of CANB common stock was charged to consulting fees in the three months ended March 31, 2017.four years.


On February 13, 2017,January 28, 2019, the Company issued 1,685,900 shares of CANB common stock to the brother of the Chief Executive Officer of the Company in satisfaction of notes payable of $15,000 and accrued interest payable of $1,859.


On March 22, 2017, the Company issued 6,785,316 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $5,979.


On April 17, 2017, the Company issued 5,000,00010,000,000 shares of CANB common stock to a consultant for services rendered. The $125,000 fair value of the 5,000,000 sharesCompany in exchange for the retirement of 1 share of CANB common stock was chargedSeries A Preferred Stock.

From February 21, 2019 to consulting fees in the three months ended June 30, 2017.


On June 21, 2017,March 12, 2019, the Company issued 250,000aggregately 20,221,436 shares of CANB common stock to a consultant for services rendered. The $5,975 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2017.


On June 28, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2017.


On August 25, 2017, the Company issued 7,142,857 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $3,331.


On August 25, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2017.


On September 5, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,375 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2017.


On September 7, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $32,750 fair value of the 2,500,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2017.




On September 11, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered, respectively. The $3,350 fair value of each 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2017.


On September 25, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $2,525 fair value of the 2,500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2017.


On November 2, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $1,725 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended December 31, 2017.


On November 9, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $21,250 fair value of the 2,500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31, 2017.


On November 30, 2017, the Company issued 50,000,000 shares of CANB common stock to Mckenzie Webster LimitedRedDiamond in exchange for the retirement of 5157,105 shares of CANB Series AB Preferred Stock.


On December 5, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered, respectively. The $3,000 fair value of each 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31, 2017.NOTE 11 – Common Stock


On December 7, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31, 2017.


On December 18, 2017, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $9,050 fair value of the 500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31, 2017.


On December 25, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered, respectively. The $7,250 fair value of each 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31, 2017.


On February 7, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $9,825 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.


On February 9, 2018, the Company issued 3,000,000 and 3,000,000 shares of CANB common stock to its two directors for services rendered, respectively. The $101,400 fair value of each 3,000,000 shares of CANB common stock was charged to directors fees in the three months ended March 31, 2018. The shares issued to one of the directors were converted to options at June 11, 2018 (see Note 10).


On February 13, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,085 fair value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.


On February 14, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.




15

On February 19, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,280 fair value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.


On February 26, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,375 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.


On March 1, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,900 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018.


On March 20, 2018, the Company issued250,000issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,500 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018.


On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, the Company issued 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock to RedDiamond in exchange for the retirement of 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock, respectively.


On May 9, 2018, the Company issued 125,000 shares of CANB common stock to a consultant for services rendered.. The $1,812 fair value of the 125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On May 29, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On May 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,600 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.


On June 4, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On June 11, 2018, the Company agreed to issue 2,749,429 shares of CANB common stock to a lender in satisfaction of notes payable of $15,000 and accrued interest payable of $4,246. The shares was issued at August 24, 2018.


On June 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,250 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On June 22, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,250 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.



From July 24, 2018 to September 26, 2018, the Company issued aggregately 53,839,743 shares of CANB common stock to RedDiamond in exchange for the retirement of 263,263 shares of CANB Series B Preferred Stock.

On July 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,225 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018.


16

On August 9, 2018, Company received a conversion notice from a lender. As a result, 9,544,292 shares of CANB common stock was issued to the lender in satisfaction of notes payable of $50,000 and accrued interest payable of $7,266 at August 21, 2018.

On August 28, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $159,600 fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 6, 2018, the Company issued 300,000 shares of CANB common stock to a consultant for services rendered. The $16,500 fair value of the 300,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 6, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $27,500 fair value of the 500,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018.

On September 6, 2018, the Company issued 8,430,331 shares of CANB common stock to a lender in satisfaction ofnotes payable of $38,500 and accrued interest payable of $7,867.

On September 7, 2018, the Company issued 5,121,694 shares of CANB common stock to a lender in satisfaction ofnotes payable of $25,000 and accrued interest payable of $3,169.

On September 7, 2018, the Company issued 10,045,667 shares of CANB common stock to a lender in satisfaction ofnotes payable of $50,000 and accrued interest payable of $10,274.

On September 8, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 10, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $19,950 fair value of the 500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 17, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $13,725 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 20, 2018, the Company issued 7,407,407 shares of CANB common stock to an investor pursuant to a Stock Purchase Agreement dated September 17, 2018, in exchange for proceeds of $200,000, or $0.027 per CANB common share.

On September 21, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $14,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 25, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $97,400 fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

From October 2, 2018 to November 7, 2018, the Company issued aggregately 13,094,733 shares of CANB common stock to RedDiamond in exchange for the retirement of 101,736 shares of CANB Series B Preferred Stock.

17

From November 5, 2018 to December 28, 2018, the Company issued aggregately 2,125,000 shares of CANB common stock to multiple consultants for services rendered. The $80,665 fair value of the 2,125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 30, 2018.

From December 3, 2018 to December 28, 2018, the Company issued aggregately 1,500,000 shares of CANB common stock to three board members for services rendered. The $62,342 fair value of the 1,500,000 shares of CANB common stock was charged to director fees in the three months ended December 30, 2018.

From December 3, 2018 to December 28, 2018, the Company issued aggregately 22,413,794 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $650,000.

On December 11, 2018, the Company issued 891,089 shares of CANB common stock to RedDiamond in satisfaction of dividend payable of $9.000.

On December 19, 2018, the Company issued 891,089 shares of CANB common stock to Auctus, LLC pursuant to a cashless exercise of stock options.

On December 21, 2018, Company received a conversion notice from a lender. As a result, 9,372,100 shares of CANB common stock was issued to the lender in satisfaction of notes payable of $83,500 and accrued interest payable of $10,221.

On December 21, 2018, Company issued aggregately 4,370,629 shares of CANB common stock to four officers of the Company in satisfaction of accrued compensation of $192,300.

On December 28, 2018, the Company issued 3,096,827 shares of CANB common stock for the acquisition of Pure Health Products, LLC.

On December 28, 2018, the Company issued 245,789 shares of CANB common stock to an officer of the Company pursuant to the Employment Agreement dated December 29, 2018 with Andrew Holtmeyer. The $10,371 fair value of the issuance was charged to stock-based compensation in the three months ended December 31, 2018.

On December 29, the Company issued 30,000,000 shares of CANB common stock to Marco Alfonsi in exchange for the return of 3 shares of CANB Series A Preferred Stock owned by Marco Alfonsi.

From January 4, 2019 to March 27, 2019, the Company issued aggregately 41,431,994 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100.

On January 14, 2019, the Company issued 7,500,000 shares of CANB common stock to Hudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for purchase of the technology owned by HUDI.

From January 18, 2019 to March 17, 2019, the Company issued aggregately 24,600,000 shares of CANB common stock to multiple consultants for services rendered.

From January 19, 2019 to March 27, 2019, the Company issued aggregately 1,167,959 shares of CANB common stock to employee and officers of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March 31, 2019.

On February 5, 2019, the Company issued 2,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018.

On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to owners of Seven Chakras pursuant to an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC dated January 31, 2019.

NOTE 1012 – Stock Options and Warrants


A summary of stock options and warrants activity follows:


 

Shares of Common Stock Exercisable Into

 

Stock

 

 

 

 

 

Options

 

Warrants

 

Total

Balance, December 31, 2016

50,000

 

247,500

 

297,500

Granted in 2017

-

 

-

 

-

Expired in 2017

-

 

-

 

-

 

 

 

 

 

 

Balance, December 31, 2017

50,000

 

247,500

 

297,500

Granted in 1Q, 2Q 2018

3,000,000

 

-

 

3,000,000

Cancelled in 1Q, 2Q 2018

-

 

-

 

-

 

 

 

 

 

 

Balance, June 30, 2018

3,050,000

 

247,500

 

3,297,500

  Shares of Common Stock Exercisable Into 
  Stock       
  Options  Warrants  Total 
Balance, December 31, 2017  50,000   247,500   297,500 
Granted in 2018  6,000,000   2,850,000   8,850,000 
Cancelled in 2018  -   -   - 
Exercised in 2018  -   (850,000)  (850,000)
             
Balance, December 31, 2018  6,050,000   2,247,500   8,297,500 
Granted in Q1 2019  -   -   - 
Cancelled in Q1 2019  -   -   - 
Exercised in Q1 2019  -   -   - 
             
Balance, March 31, 2019  6,050,000   2,247,500   8,297,500 


18

Issued and outstanding stock options as of June 30, 2018March 31, 2019 consist of:


Year

 

Number Outstanding

 

 

Exercise

 

Year of

Granted

 

And Exercisable

 

 

Price

 

Expiration

 

 

 

 

 

 

 

 

2009

 

50,000

 

$

1.000

 

2019

2018

 

3,000,000

 

$

0.001

 

2023

 

 

 

 

 

 

 

 

Total

 

3,050,000

 

 

 

 

 


Year Number Outstanding  Exercise  Year of 
Granted And Exercisable  Price  Expiration 
          
2009  50,000  $1.000   2019 
2018  6,000,000  $0.001   2023 
             
Total  3,050,000         

On June 11, 2018, the Company granted 3,000,000 options of CANB common stock to Carl Dilley, a former director of the Company, in exchange for the retirement of a total of 3,000,000 shares of CANB common stock from Carl Dilley. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire June 11, 2023. The value of the Stock Options ($84,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.028 share price, (ii) 5 years term, (iii) 262.00% expected volatility, (iv) 2.80% risk free interest rate and the difference between this value and the fair value of retired shares was expensed in the quarterly period ended June 30, 2018.


On October 21, 2018, the Company granted 3,000,000 options of CANB common stock to Stanley L. Teeple, an officer and Director of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 1, 2023. The values of the Stock Options ($118,200) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.0395 share price, (ii) 5 years term, (iii) 221.96% expected volatility, (iv) 3.05% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2018

Issued and outstanding warrants as of June 30, 2018March 31, 2019 consist of:


Year

 

Number Outstanding

 

 

Exercise

 

Year of

 Number Outstanding Exercise  Year of 

Granted

 

And Exercisable

 

 

Price

 

Expiration

 And Exercisable  Price  Expiration 

 

 

 

 

 

 

 

        

2010

 

247,500

 

$

1.00

 

2020

  247,500  $1.00   2020 
2018  2,000,000  $0.04345(a)  2023 

 

 

 

 

 

 

 

            

Total

  2,247,500         




(a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.


NOTE 1113 – Income Taxes


No provisions for income taxes were recorded for the periods presented since the Company incurred net losses in those periods.


19

The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% and 35% to pretax income (loss) as follows:


 

 

Six Months June 30,

 

 

2018

 

2017

 

 

 

 

 

Expected income tax (benefit) at 21% and 35%

$

(119,137)

 

$

(169,522)

 

 

 

 

 

Loss on stock issuance

 

38,872 

 

 

 

 

 

 

Loss on debt conversion

 

12,125 

 

 

 

 

 

 

Non-deductible stock-based compensation

159,217 

 

13,030 

 

 

 

 

 

Non-deductible amortization of debt discounts

11,375 

 

53,587 

 

 

 

 

Non-deductible expense from derivative liability

(177,251)

 

18,779 

 

 

 

 

Increase in deferred income tax assets 

 

 

 

 

  valuation allowance

 

74,799 

 

84,126 

 

 

 

 

 

Provision for (benefit from) income taxes

 

$

 

$

  Three Months March 31, 
  2019  2018 
       
Expected income tax (benefit) at 21% $(246,228) $85,587 
         
Non-deductible stock-based compensation  173,921   90,449 
         
Non-deductible amortization of debt discounts  -   5,977 
         
Non-deductible expense from derivative liability  -   (225,898)
         
Increase in deferred income tax assets valuation allowance  72,307   43,885 
         
Provision for (benefit from) income taxes $-  $- 


Deferred income tax assets consist of:


 

June 30,

 

December 31,

 March 31, December 31, 

 

2018

 

2017

 2019  2018 

 

 

 

 

     

Net operating loss carryforward

 

1,469,157 

 

1,394,358 

  1,716,900   1,644,593 

 

 

 

 

        

Valuation allowance

 

(1,469,157)

 

(1,394,358)

  (1,716,900)  (1,644,593)

 

 

 

 

        

Net

 

$

 

$

 $-  $- 


Based on management'smanagement’s present assessment, the Company has not yet determined it to be more likely than not that a deferred income tax asset of $1,469,157$1,716,900 attributable to the future utilization of the $4,329,487$5,131,252 net operating loss carryforward as of June 30,December 31, 2018 will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred income tax asset in the financial statements at DecemberMarch 31, 2017.2019. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforward expires in years 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038 and 20382039 in the amount of $1,369, $518,390, $594,905, $686,775, $159,141, $151,874, $135,096, $166,911, $311,890, $25,511, $338,345, $386,297, $496,798, $713,162 and $356,185$344,318, respectively.

 




Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited.


The Company’s U.S. Federal and state income tax returns prior to 20132014 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The statute of limitations on the 20132014 tax year returns expired in March 2017.September 2018.


The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the consolidated balance sheets. There were no interest or penalties paid during 2018 and 2017.

20


NOTE 1214 – Commitments and Contingencies


Employment Agreements


On October 3, 2017, the Company executed an Executive Employment Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi to serve as the Company'sCompany’s chief executive officer and interim chief financial officer and secretary for cash compensation of $10,000 per month. Pursuant to the agreement, the Company issued a share of CANB Series A Preferred Stock to Alfonsi on October 4, 2017 (see Note 8). Alfonsi may terminate his employment upon 30 days written notice to the Company. The Company may terminate Alfonsi'sAlfonsi’s employment upon written notice to Alfonsi by a vote of the Board of Directors. At November 12, 2018, this Agreement was terminated due to the execution of a new Employment Agreement with Marco Alfonsi for Alfonsi to serve as the Company’s chief executive officer for cash compensation of $15,000 per month. Pursuant to the agreement, three of the eight previously issued shares of CANB Series A Preferred Stock will be returned to the Company and converted into 30,000,000 common shares. On December Alfonsi may terminate his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Alfonsi, and also can be terminated by the Company due to the failure or neglect of Mr. Alfonsi to perform his duties, or due to the misconduct of Mr. Alfonsi in connection with the performance.


On February 12, 2018, the Company executed an Executive Service Agreement (“Agreement”) with David Posel. The Agreement provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Agreement also provides for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Posel, and also can be terminated by the Company due to the failure or neglect of Mr. Posel to perform his duties, or due to the misconduct of Mr. Posel in connection with the performance. On February 12, 2018, 1 share of CANB Series A Preferred Stock were issued to Mr. Posel (see Note 8). Since execution of the Posel Agreement, Mr. Posel has been re-assigned to COO for Pure Health Products, the Company’s subsidiary.


On February 16, 2018, the Company executed an Executive Service Agreement (“Agreement”) with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 3 years. The Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of Series A Preferred Stock at the beginning of each year. The Agreement can be terminated upon the resignation or death of Mr. Holtmeyer, and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer to perform his duties, or due to the misconduct of Mr. Holtmeyer in connection with the performance. On February 16,At December 29, 2018, 3this Agreement was terminated due to the execution of a new Employment Agreement with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 4 years. The Agreement also provides for compensation to Mr. Holtmeyer of $15,000 cash per month and the issuance of 245,789 shares of CANBcommon stock upon signing of the agreement.

On October 15, 2018, the Company executed an Employment Agreement (“Agreement”) with Stanley L. Teeple. The Agreement provides that Mr. Teeple services as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Agreement also provides for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock were issuedupon execution of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Teeple, and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer (see Note 8).Teeple to perform his duties, or due to the misconduct of Mr. Teeple in connection with the performance.


Consulting Agreements


On July 29, 2017,December 28, 2018, the Company executed a Consultingan Employment Agreement (“Agreement”) withAndrew W Holtmeyer Pasquale Ferro for Mr. HoltmeyerFerro to serve as Pure Health Products’ president for cash compensation of $15,000 per month and the Company's consultanttotal issuance of 5 share of Series A Preferred Stock proportionately vesting at the beginning of each year for monthly cash paymenta term of $5,000 through July 29, 2018. Effective February 16, 2018,4 years. Mr. Ferro may terminate his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Ferro, and also can be terminated by the Company terminated the agreement due to the replacementfailure or neglect of an Executive Service Agreement.Mr. Ferro to perform his duties, or due to the misconduct of Mr. Ferro in connection with the performance.


21

Consulting Agreements

On September 6, 2017, the Company executed a Consulting Agreement with T8 Partners LLC (“T8”) for T8 to serve as the Company'sCompany’s consultant for stock compensation of a total of 10,000,000 restricted shares. Pursuant to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to T8 on September 7, 2017. Effective October 27, 2017, the Company terminated the agreement due to non-performance by T8. The Company won the arbitration proceedings against T8 and T8 has been ordered to return its shares to the Company.




On November 9, 2017, the Company executed a Consulting Agreement with Healthcare Advisory Group Company (“Healthcare”) for Healthcare to serve as the Company'sCompany’s consultant for stock compensation of a total of 5,000,000 restricted shares. Pursuant to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to Healthcare on November 9, 2017. Effective March 6, 2018, the Company terminated the agreement due to non-performance by Healthcare.


Lease Agreements


On December 1, 2014, Prosperity entered into a lease agreement with KLAM, Inc. for office space in Hicksville, New York for an initial term of one year commencing December 1, 2014. The lease provides for monthly rentals of $2,500 and provides Prosperity an option to renew the lease after the initial term. The Company has continued to occupy this space after November 30, 2015 under a month to month arrangement at $2,500 per month. KLAM, Inc. is controlled by the wife of the Company'sCompany’s chief executive officer Marco Alfonsi.


On September 11, 2015, the Company executed a lease agreement with an unrelated third party for office space in Hicksville, New York for a term of 37 months. The lease provides for monthly rentals of $2,922 for lease year 1, $3,009 for lease year 2, and $3,100 for lease year 3. The lease also provides for additional rent based on increases in base year operating expenses and real estate taxes. On August 6, 2018, the Company renewed the lease agreement for a term of 36 months starting November 1, 2018. The lease provides for monthly rentals of $3,193 for lease year 1, $3,289 for lease year 2, and $3,388 for lease year 3.


Rent expense for the six monthsyear ended June 30,December 31, 2018 and 2017 was $33,065$67,165 and $32,530,$65,060, respectively.


At June 30, 2018,March 31, 2019, the future minimum lease payments under non-cancellable operating leases were:


Year ended December 31, 2019  28,932 
Year ended December 31, 2020  39,666 
Year ended December 31, 2021  33,880 
Total $102,478 

Year ended DecemberThe lease liability of $90,591 at March 31, 2018

    9,300


Total2019 as presented in the Consolidated Balance Sheet represents the discounted (at our 10% estimated incremental borrowing rate) value of the future lease payments of 102,478 at March 31, 2019.

 $ 9,300


Major Customers


For the sixthree months ended June 30,March 31, 2019, there were no customers that accounted for more than 10% of total revenues.

For the three months ended March 31, 2018, one customer accounted for approximately 14%13% of total revenues.


For the six months ended June 30, 2017, two customers accounted for approximately 45% and 29%, respectively, of total revenues.


Public Offering of Units


On August 2, 2016, the Company’s Registration Statement on Form S-1 was declared effective by the Securities and Exchange Commission. On a self-underwritten basis, the Company is offering up to 40,000,000 Units at a price of $0.05 per Unit or $2,000,000 maximum. Each Unit consists of one share of Company common stock and one warrant to purchase ½ share of Company common stock at a price of $0.10 per share for a period of three years. There is no minimum offering amount or escrow required as a condition to closing and the Company may sell significantly fewer Units than those offered. The offering will terminate on August 2, 2018 unless earlier terminated or extended by the Company’s filing of an amendment to the Registration Statement. To date, no Units have been sold.




NOTE 1315 – Related Party Transactions


ProAdvanced Group, Inc. (“PAG”), an entity controlled by the Company’s chief executive officer, is a customer of CANB. At June 30, 2018,March 31, 2019, CANB had an account receivable from PAG of $7,240. For the sixthree months ended June 30, 2018,March 31, 2019, CANB had revenues from PAG of $5,000.$0.


Island Stock Transfer (“IST”), an entity controlled by Carl Dilley, a former Company director, is both a customer and vendor of CANB. At June 30, 2018,March 31, 2019, CANB had an account receivable from IST of $6,035 and an account payable to IST of $2,138.$7,932. For the sixthree months ended June 30, 2018,March 31, 2019, CANB had revenues from IST of $3,000.$0.


Stock Market Manager, Inc. is also an entity controlled by Mr. Dilley. For the sixthree months ended June 30, 2018,March 31, 2019, CANB had an account payable to Stock Market Manager Inc. of $1,676.


In order to facilitate its operations, the Company has entered into a Production Agreement with Pure Health Products, LLC (“PHP”), a New York limited liability company. Pursuant to the Production Agreement, PHP will manufacture, package, and sell the Company’s CBD infused products on an exclusive basis. PHP will not produce or manufacture any product containing any cannabis or hemp derivative for any person or entity other than the Company, and the Company controls the ingredients, recipe, manufacturing processes and procedures and quality and taste parameters for all Products produced at the PHP facility. PHP may also white label / rebrand or relabel the products on the Company’s behalf pursuant to “white label agreements” entered into between the Company and third-party customers. Credit card sales are processed through PHP as well. Through its contractual relationship with PHP, the Company is able to control the manufacturing process of its products while reducing its production costs. In addition, the Company has the option to acquire certain assets of PHP should it elect to take over direct manufacture of its Products. For the six months ended June 30, 2018, purchase of CBD infused products from PHP totaled $79,754.     


At June 30, 2018, we have a note receivable from PHP in the amount of $75,000. PHP is controlled by Pasquale Ferro. At June 30, 2018, we are indebted to Mr. Ferro and his wife Rosemary Ferro in the amount of $113,500.


The Company considers Pure Health products to be a variable interest entity as prescribed under Accounting guidelines. Due to the fact that the company is not dependent on Pure Health Products solely for manufacture, no consolidation of Pure Heath Products financial information is required.


During the sixthree months ended June 30, 2018,March 31, 2019, we had products and service sales to related parties totaling $0.


NOTE 1416 – Subsequent Events


On August 6, 2018, the Company and its third party landlord executed a First AmendmentFrom April 29, 2019 to Lease (see Note 12). The amendment provides for the extension of the lease term for an additional three years commencing on NovemberMay 1, 2018 and ending on October 31, 2021 at monthly rental of $3,193 for year 1, $3,289 for year 2, and $3,388 for year 3.


On August 9, 2018, Company received a conversion notice from a lender. As a result, 9,544,292 shares of CANB common stock will be issued to the lender in satisfaction of notes payable of $50,000 and accrued interest payable of $7,266.


On August 13, 2018, the Company and Pasquale and Rosemary Ferro executed an Addendum to 12% Convertible Promissory Note (the “Addendum”). The Addendum provides for an increase in the maximum principal amount of the Note facility to $300,000 and extends the maturity date of the Note to June 30, 2021. The principal balance of the notes payable due to Pasquale and Rosemary Ferro under the Note facility at June 30, 2018 was $113,500 (see Note 7).




On July 12, 2018, the Company received a response from T8 Partners LLC (“T8”) confirming that the 2,500,000 shares requested to be returned by the Company in an arbitration filed on May 11, 2018 will be returned to the Company.


On July 31, 2018,2019, the Company issued 250,000aggregately 4,504,950 shares of CANB common stock to a consultantRedDiamond in exchange for services rendered. The $3,225 fair valuethe retirement of the 250,00035,000 shares of CANB common stock will be charged to consulting fees in the three months ended September 30, 2018.Series B Preferred Stock.


In accordance with FASB ASC 855, Subsequent Events, , the Company has evaluated subsequent events through August 16, 2018,May 17, 2019, the date on which these consolidated financial statements were available to be issued. Except as disclosed above, there were no material subsequent events that required recognition or additional disclosure in these consolidated financial statements.




22

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


General


Canbiola, Inc. was originally formed as a Florida corporation on October 11, 2005, under the name of WrapMail, Inc. Effective January 5, 2015, we acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), which the Company is in the process of dissolving. Effective December 28, 2018, we acquired 100% ownership of Pure Health Products. In November 2018, we formed Duramed as a New York corporation incorporated on April 2, 2008. We provide document, project, marketing and sales management systems to business clients through our website and proprietary software and also have a division focusing on the development and sale of products containing CBD.wholly-owned subsidiary. The Company is presently in the process of dissolving Prosperity.


We manufacture and sell products containing CBD. We also provide document, project, marketing and sales management systems to our residual business clients through our website and proprietary software, which divisions are being wound-down. The consolidated financial statements include the accounts of CANB and its wholly owned subsidiary Prosperity fromPure Health Products and DuraMed for the date of its acquisition on January 5, 2015.three months ended March 31, 2019.


Results of Operations


Three Months Ended June 30, 2018March 31, 2019 compared with Three Months Ended June 30, 2017:March 31, 2018:


Revenues increased $128,321$447,391 from $25,870$69,769 in 20172018 to $154,191$517,160 in 2018.2019.


Cost of product sales increased $45,713$217,966 from $1,139 in 2017 to $46,852$44,587 in 2018 to $262,553 in 2019 due to the expansion of current product sales and launch of new product sales.sales in Duramed.


Officers and director’s compensation increased $182,750 from $262,800 in 2018 to $445,550 in 2019. The 2019 expense amount(445,550) includes stock-based compensation($262,420) paid to officers and payroll taxes increased $56,873 from $19,377 in 2017 to $76,250 in 2018.employees. The 2018 expense amount ($76,250) consists of compensations accrued to our Chief Executive Officer262,800) includes stock-based compensation ($30,000), Executive Vice President Business Development ($30,000) and compensation202,800) paid to Chief Operating Officer ($16,250) pursuant to their respective employment or service agreements. The 2017 expense amount ($19,377) consists of salaries accrued to our Chief Executive Officer ($18,000) pursuant to their respective employment agreements and related payroll taxes ($1,377).the advisory board members.


Consulting fees increased $312,687$387,843 from $55,082$275,908 in 20172018 to $367,769$663,751 in 2018.2019. The 20182019 expense amount ($367,769)663,751) includes stock-based compensation of $344,869, resulting from stock issued for the service of consultants.The 2017 expense amount ($55,082) includes stock-based compensation of $26,229, resulting from stock issued for the service of a consultants.


Directors fees decreased from $0 in 2017 to ($17,400) in 2018.


Advertising expense decreased $6,218 from $20,893 in 2017 to $14,675 in 2018.  


Hosting expense decreased $8,436 from $12,246 in 2017 to $3,810 in 2018.


Rent expense increased $535 from $16,265 in 2017 to $16,800 in 2018.


Professional fees increased $10,198 from $46,758 in 2017 to $56,956 in 2018.


Depreciation of property and equipment decreased $6 from $807 in 2017 to $801 in 2018.  


Amortization of intangible assets decreased $993 from $993 in 2017 to $0 in 2018.




Other operating expenses increased $17,338 from $38,775 in 2017 to $56,113 in 2018. The increase was due largely to higher travel expense and supplies expenses in 2018 compared to 2017.


Net loss increased from $508,448 in 2017 to $974,876 in 2018. The increase was due to the $281,940 increase in total operating expenses and the increase of $184,458 in other expense – net from $321,983 other expense – net in 2017 to $506,441 other expense– net in 2018, and the $128,321 increase in revenues.


Six Months Ended June 30, 2018 compared with Six Months Ended June 30, 2017:


Revenues increased $180,118 from $43,842 in 2017 to $223,960 in 2018.


Cost of product sales increased $90,300 from $1,139 in 2017 to $91,439 in 2018 due to the launch of new product sales.


Officers compensation and payroll taxes increased $97,418 from $38,832 in 2017 to $136,250 in 2018. The 2018 expense amount ($136,250) consists of compensations accrued to our Chief Executive Officer ($60,000), Executive Vice President Business Development ($52,500) and compensation paid to Chief Operating Officer ($23,750) pursuant to their respective employment or service agreements. The 2017 expense amount ($38,832) consists of salaries accrued to our Chief Executive Officer ($36,000) pursuant to their respective employment agreements and related payroll taxes ($2,832).


Consulting fees increased $571,894 from $71,782 in 2017 to $643,676 in 2018. The 2018 expense amount ($643,676) includes stock-based compensation of $572,777,$565,776, resulting from stock issued for the service of consultants. The 20172018 expense amount ($71,782)275,908) includes stock-based compensation of $37,229,$11,000, resulting from stock issued for the service of a consultants.


Directors fees increased $185,400 from $0 in 2017 to $185,400 in 2018. The 2018 expense amount ($185,400) are stock-based compensation paid to two directors of the Company.


Advertising expense increased $15,498$4,055 from $21,510$22,333 in 20172018 to $37,008$26,388 in 2018.  2019.


Hosting expense decreased $7,208$3,218 from $14,687$3,668 in 20172018 to $7,479$450 in 2018.2019.


Rent expense increased $535decreased $4,405 from $32,530$16,265 in 20172018 to $33,065$11,860 in 2018.2019.


Professional fees increased $7,603$24,453 from $62,736$13,383 in 20172018 to $70,339$37,836 in 2018.2019.


Depreciation of property and equipment decreased $10increased $1,962 from $1,614$803 in 20172018 to $1,604$2,765 in 2018.  2019.


Amortization of intangible assets decreased $1,986increased $2,194 from $1,986 in 2017 to $0 in 2018.2018 to $2,194 in 2019.


Other operating expenses increased $60,038$171,168 from $60,519$64,713 in 20172018 to $120,827$235,881 in 2018.2019. The increase was due largely to higher referral fees, travel expense, and supplies expensesnews announcement fees in 2019 compared to 2018.

Net income decreased $1,580,072 from income of $407,558 in 2018 compared to 2017.


Neta loss increased from $484,348of $1,172,514 in 2017 to $567,318 in 2018.2019. The increasedecrease was due to the $839,633$766,802 increase in total operating expenses offset byand the increasedecrease of $756,663$1,042,695 in other income – net from $220,855$1,042,249 other expenseincome – net in 20172018 to $535,808$446 other income–expense– net in 2018, and2019, offset by the $180,118$447,391 increase in revenues.




23

Liquidity and Capital Resources


At June 30, 2018,March 31, 2019, we had cash and cash equivalents of $73,572$567,291 and negative working capital of $534,406.$1,067,641.


Cash and cash equivalents increased $71,920decreased $240,456 from $1,652$807,747 at December 31, 20172018 to $73,572$567,291 at June 30, 2018.March 31, 2019. For the sixthree months ended June 30, 2018, $384,000March 31, 2019, $1,194,265 was provided by financing activities, $38,355$744,212 was used in investing activities, and $273,725$690,509 was used in operating activities.


We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.


We currently have no commitments with any person for any capital expenditures.


We have no off-balance sheet arrangements.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

None.

 

ITEM 4. CONTROLS AND PROCEDURES

 

(A) EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

As of June 30, 2018,March 31, 2019, our principal executive officer and principal financial officer conducted an evaluation regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act). Based upon the evaluation of these controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report.

 

(B) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

There were no changes in our internal control over financial reporting in our first fiscal quarter for the period ended June 30, 2018March 31, 2019 covered by this Quarterly Report on Form 10-Q, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

 





PART II-OTHERII - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

On May 11, 2018, the Company brought an arbitration proceeding 9American Arbitration Association case 01-18-001-8823) against T8 Partners, Inc. (“T8”). The claim alleged that T8 failedWe are not currently a party to perform certain services agreed to in a Consulting Agreement dated September 6, 2017 and sought return at 2,500,000 shares of CANB common stock issued to T8 on September 7, 2017. On July 12, 2018, the Company was notified by T8 that T8 had requested its broker dealer to return the certificate for 2,500,000 shares to the Company for cancellation. As of the date of this filing, the return of the 2,500,000 shares has not yet occurred.any legal proceedings.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to provide risk factors in this Form 10-Q.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Sales of unregistered securities during the quarterly period ended June 30, 2018March 31, 2019 follows:


On February 7, 2018,From January 4, 2019 to March 27, 2019, the Company issued 250,000aggregately 41,431,994 shares of CANB common stock to a consultantmultiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for services rendered. The $9,825 fair valuetotal proceeds of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.$1,196,100.


On February 9, 2018,January 14, 2019, the Company issued 3,000,000 and 3,000,0007,500,000 shares of CANB common stock to its two directorsHudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for services rendered, respectively. The $101,400 fair valuepurchase of each 3,000,000 shares of CANB common stock was chargedthe technology owned by HUDI.

24

From January 18, 2019 to directors fees in the three months ended March 31, 2018.


On February 13, 2018,17, 2019, the Company issued 150,000aggregately 24,600,000 shares of CANB common stock to a consultantmultiple consultants for services rendered. The $5,085 fair value of the 150,000 shares of CANB common stock was partially charged

From January 19, 2019 to consulting fees in the three months ended March 31, 2018.


On February 14, 2018,27, 2019, the Company issued 250,000aggregately 1,167,959 shares of CANB common stock to a consultant for services rendered. The $8,500 fair valueemployee and officers of the 250,000 sharesCompany pursuant to employee agreement and in satisfaction of CANB common stock was partially charged to consulting fees inaccrued compensation for the three monthsquarter ended March 31, 2018.2019.


On February 19, 2018,5, 2019, the Company issued 150,0002,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018.

On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to a consultant for services rendered. The $5,280 fair valueowners of the 150,000 shares of CANB common stock was partially chargedSeven Chakras pursuant to consulting fees in the three months ended Marchan Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC dated January 31, 2018.2019.


On February 26, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,375 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.


On March 1, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,900 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018.


On March 20, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,500 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018.




On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, the Company issued 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock to RedDiamond in exchange for the retirement of 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock, respectively.


On May 9, 2018, the Company issued 125,000 shares of CANB common stock to a consultant for services rendered The $1,812 fair value of the 125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On May 29, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On May 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,600 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.


On June 4, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On June 11, 2018, the Company agreed to issue 2,749,429 shares of CANB common stock to a lender in satisfaction of notes payable of $15,000 and accrued interest payable of $4,246.


On June 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,250 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.


On June 22, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,250 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.


With respect to the transactions noted above, each of the recipients of securities of the Company was an accredited investor, or is considered by the Company to be a “sophisticated person”, inasmuch as each of them has such knowledge and experience in financial and business matters that they are capable of evaluating the merits and risks of receiving securities of the Company. No solicitation was made and no underwriting discounts were given or paid in connection with these transactions. The Company believes that the issuance of its securities as described above was exempt from registration with the Securities and Exchange Commission pursuant to Section 4(a)(2) of the Securities Act of 1933.


ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.




ITEM 6. EXHIBITS


3.1

3.1

Articles of Incorporation, as amended*

3.2

Bylaws*

31.1

Rule 13a-14(a)/15d-14(a) certification of Chief Executive Officer

certification under Section 302 of the Sarbanes-Oxley Act of 2002

32.1

31.2

Chief Financial Officer certification under Section 1350 certification302 of the Sarbanes-Oxley Act of 2002

32.1Chief Executive Officer

certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

99.1

32.2

AmendmentChief Financial Officer certification pursuant to Articles18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Incorporation and Certificatethe Sarbanes-Oxley Act of Designations for Series B Preferred Stock **

2002

99.2

101.INS

Certificate of Designations for Series B Preferred Stock***

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Linkbase Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension LabelLabels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

*

filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated

herein by reference.


**       filed with the Form 8-K filed with the SEC on November 15, 2017 and incorporated herein by reference.


***     filed with the Form 8-K filed with the SEC on October 18, 2017 and incorporated herein by reference.

 

25




SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

CANBIOLA, INC.

CANBIOLA, INC.

Date: June 17, 2019

By:

Date: September 20, 2018

By:

/s/ Marco Alfonsi

Marco Alfonsi, Chief Executive Officer

Date: June 17, 2019

By:

/s/ Stanley L. Teeple

Stanley L. Teeple, Chief Financial Officer

 

26









33